Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Eric J, Kruep"'
Publikováno v:
American Journal of Men's Health, Vol 7 (2013)
Although there is an abundance of evidence regarding clinical efficacy and safety of benign prostatic hyperplasia (BPH) treatment, real-world evidence is lacking for pharmacotherapy utilization and trends. It is unclear how evidence demonstrating the
Externí odkaz:
https://doaj.org/article/a22486cb193548d78655c61d9bb4a9cc
Publikováno v:
World Journal of Urology. 34:1107-1113
To assess the prostate-specific antigen (PSA) threshold value that optimally predicts future risk of prostate cancer (overall and by race) for a dispersed US population. This was a retrospective analysis of men in the Veterans Affairs (VA) Health Car
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55cf03d823816595ae341b9c6caa267b
https://doi.org/10.1007/s00345-015-1754-6
https://doi.org/10.1007/s00345-015-1754-6
Publikováno v:
Current Medical Research and Opinion. 25:2663-2669
Pharmacologic treatment of lower urinary tract symptoms from benign prostatic hyperplasia (BPH) commonly includes alpha-blockers (ABs) and 5alpha-reductase inhibitors (5ARIs). Many clinicians use ABs for rapid symptom control and 5ARIs to modify long
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b29fe5c4617d4daa9090de635198dc08
https://doi.org/10.1185/03007990903210330
https://doi.org/10.1185/03007990903210330
Autor:
Eric J. Kruep, Lorne E. Basskin
Publikováno v:
American Journal of Health-System Pharmacy. 62:2597-2603
Purpose. The cost of darbepoetin alfa versus that of epoetin alfa in a hospital setting was studied. Methods. The study was an observational, retrospective review of the hospitalwide use of darbepoetin and epoetin during hospital admissions beginning
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13160d68e4c8f68db7ba9257199296da
https://doi.org/10.2146/ajhp040565
https://doi.org/10.2146/ajhp040565
Publikováno v:
American healthdrug benefits. 4(3)
Pharmacologic treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia often includes alpha-blockers and 5-alpha reductase inhibitors. Many clinicians use alpha-blockers for rapid symptom control, later adding 5-alpha re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7297d78c2a107c4f2bee101170c1307a
https://pubmed.ncbi.nlm.nih.gov/25126348
https://pubmed.ncbi.nlm.nih.gov/25126348
Publikováno v:
The Annals of pharmacotherapy. 48(3)
Background: Pharmacological treatment options for benign prostatic hyperplasia (BPH) commonly include α-blocker (AB) and 5-α-reductase inhibitor (5ARI) agents, which have separate but important attributes that carry clinical implications in terms o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ff16b05523284a0b8eca073c517a99d
https://pubmed.ncbi.nlm.nih.gov/24311727
https://pubmed.ncbi.nlm.nih.gov/24311727
Publikováno v:
Expert opinion on pharmacotherapy. 13(18)
The primary objective of this study was to evaluate the length of 5-alpha reductase inhibitor (5ARI) therapy on the likelihood of acute urinary retention (AUR) and prostate surgery in patients diagnosed with benign prostatic hyperplasia (BPH). Additi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee0a02c06d8cac75b8274074302548d9
https://pubmed.ncbi.nlm.nih.gov/23163741
https://pubmed.ncbi.nlm.nih.gov/23163741
Publikováno v:
PT : a peer-reviewed journal for formulary management. 36(8)
Recent clinical trials indicate that combining an alpha blocker for rapid symptom improvement and a 5-alpha reductase inhibitor (5-ARI) to reduce the risk of clinical progression of benign prostatic hyperplasia (BPH) may be an optimal approach to man
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::34746157b44cbd58ecc3d563468dece6
https://pubmed.ncbi.nlm.nih.gov/21935297
https://pubmed.ncbi.nlm.nih.gov/21935297
Publikováno v:
Journal of Urology. 185
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86129f5f56c4db637e078505f8437e3a
https://doi.org/10.1016/j.juro.2011.02.1621
https://doi.org/10.1016/j.juro.2011.02.1621
Publikováno v:
The American journal of managed care. 14(5 Suppl 2)
To assess cost differences between dutasteride and finasteride use within the first year of initiating treatment for enlarged prostate (EP) among men agedor =65 years in a managed care setting.For this retrospective analysis, medical/pharmacy claims
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::aa548cfaed91cbb65b88c3660b5e8feb
https://pubmed.ncbi.nlm.nih.gov/18611091
https://pubmed.ncbi.nlm.nih.gov/18611091